315P Treatment patterns in black and indigenous people and people of color (BIPOC) receiving palbociclib for hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC) in a real-world setting: POLARIS study results

G Rocque,J Blum,A Montero,S Sonnier,S Mccune,C Gallagher,T Pluard,J Cappelleri,M Drucker,Y Wang,D Tripathy

doi:10.1016/j.annonc.2021.08.598

315P Treatment patterns in black and indigenous people and people of color (BIPOC) receiving palbociclib for hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC) in a real-world setting: POLARIS study results

G Rocque, J Blum + Show 9 more

Open Access

https://doi.org/10.1016/j.annonc.2021.08.598

Copy DOI

Journal: Annals of Oncology	Publication Date: Sep 1, 2021
License type: publisher-specific-oa

Affiliation: University of Alabama, Texas Oncology, Gwinnett Medical Center, Touro Infirmary Foundation, WellStar Health System, MedStar Washington Hospital Center, Saint Luke's Hospital, Pfizer (United States), The University of Texas MD Anderson Cancer Center

#Human Epidermal Growth Factor Receptor #Group In Clinical Trials + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

POLARIS is a prospective, real-world, noninterventional study in patients with HR+/HER2‒ ABC receiving palbociclib (PAL). This report describes real-world PAL use in BIPOC, an underrepresented group in clinical trials.

Full Text

Paper version not known

Open DOI Link

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title

Journal

Date

Author

View more papers

More From: Annals of Oncology

Paper Title

Journal

Date

Author

View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.